ALKEM2023-01-012023-03-31 ALKEM2023-01-012023-03-31 ALKEM2023-01-012023-03-31in-bse-fin:OneOperatingExpenses01Member ALKEM2023-01-012023-03-31in-bse-fin:FourOperatingExpenses01Member ALKEM2023-03-31 ALKEM2023-01-012023-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2023-01-012023-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2023-01-012023-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ALKEM2023-01-012023-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539523 ALKEM NOTLISTED Alkem Laboratories Limited Equity 2022-04-01 2023-03-31 2023-05-19 2023-05-09 INR Millions Yearly 11:00:00 13:30:00 2023-05-19 2023-05-19 true Cash Flow Indirect Declaration of unmodified opinion Single segment The Company is exclusively engaged in pharmaceutical business 2023-01-01 2023-03-31 Audited Consolidated 29026000000.00 686700000.00 29712700000.00 7706200000.00 3466800000.00 1382200000.00 5029800000.00 289600000.00 783200000.00 7908500000.00 26566300000.00 3146400000.00 -1029800000.00 2116600000.00 628600000.00 811200000.00 1439800000.00 0.00 676800000.00 0.00 0.00 0.00 0.00 676800000.00 -103000000.00 573800000.00 709800000.00 -33000000.00 605900000.00 -32100000.00 239100000.00 2 5.94 5.94 0.00 0.00 5.94 5.94 1. The above audited consolidated financial results of the Company were reviewed and recommended by the Audit Committee on 18 May 2023 and subsequently approved by the Board of Directors at its meeting held on 19 May 2023. The auditors have expressed an unmodified opinion on the financial results for the year ended 31 March 2023. The figures for the quarter ended 31 March 2023 and 31 March 2022 are balancing figures between audited figures in respect of full financial year and the unaudited published year-to-date figures up to 31 December 2022 and 31 December 2021 respectively, which were subjected to limited review. 2. The Company has entered into a Securities Subscription Agreement and Shareholders’ Agreement dated 23 December 2022 with Enzene Biosciences Limited, a subsidiary of the Company (“Enzene”), Eight Roads Ventures India Healthcare IV, L.P. (“Eight Roads Ventures”) and F-Prime Capital Partners Life Sciences Fund VI LP (“F-Prime Capital”) towards subscription of Compulsorily Convertible Preference Shares (‘CCPS’) by Eight Roads Ventures and F-Prime Capital in Enzene for a consideration of Rs.1,614.8 million which is equivalent to 8% of the subsidiary’s equity valuation. 3. The Group has considered indicators of impairment of its cash-generating units for factors like decline in operational performance, changes in the outlook of future profitability, and weaker market conditions, among other potential indicators. In respect of one of the manufacturing units located at St. Louis under S & B Pharma LLC, USA, a step-down subsidiary of the Company, where indicators of impairment were identified, the Group estimated the recoverable amount of the assets based on the fair value less costs to sell. The outcome of this exercise as on 31 March 2023 resulted in the Group recognizing an impairment loss of Rs 1,029.8 Million in the consolidated financial results under ‘Exceptional item’. Consequently, deferred tax assets pertaining to the above assets are no longer available for utilisation, have been derecognised in the consolidated financial statements amounting to Rs. 1,197.2 mn During the previous year, the Group has fair valued one of its investments in the USA and considering the contingencies on business projections of the investee company an amount of Rs. 149.6 million has been debited to the Statement of Profit and Loss and disclosed as an ‘Exceptional item’. 4. During the quarter ended 31 March 2023, the Company has paid a Special Dividend of Rs. 25 (Rupees Twenty five only) per equity share. In addition to the Special Dividend, the Company has also paid an interim dividend of Rs. 15 (Rupees Fifteen only) per equity share amounting to a total interim dividend of Rs. 40 (Rupees Forty only) per equity share (2000% on the face value of Rs. 2 each) for the financial year ended 31 March 2023. The Board of Directors at its meeting held on 19 May 2023 has recommended a final dividend of Rs. 10 (Rupees Ten only) per equity share (500% on the face value of Rs. 2 each) for the financial year 2022-23. 5. The Group operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. Single segment 2022-04-01 2023-03-31 Audited Consolidated 115992600000.00 2160800000.00 118153400000.00 30569200000.00 13875500000.00 4623700000.00 21313500000.00 1073600000.00 3104200000.00 29516200000.00 104075900000.00 14077500000.00 -1029800000.00 13047700000.00 2739000000.00 240600000.00 2979600000.00 0.00 10068100000.00 0.00 0.00 0.00 0.00 10068100000.00 1149000000.00 11217100000.00 9841700000.00 226400000.00 10994800000.00 222300000.00 239100000.00 2 90213800000.00 82.31 82.31 0.00 0.00 82.31 82.31 Other expenses 7908500000.00 Other expenses 29516200000.00 3897100000.00 20654000000.00 3102700000.00 4131700000.00 2042800000.00 129700000.00 3046100000.00 80200000.00 2952500000.00 6078800000.00 13025000000.00 1104983000.00 50269683000.00 26075300000.00 3172100000.00 21321800000.00 2738000000.00 23430900000.00 67700000.00 1897517000.00 52628017000.00 7360900000.00 86064217000.00 1232600000.00 137566500000.00 239100000.00 90213800000.00 90452900000.00 94350000000.00 703300000.00 1660100000.00 2363400000.00 3693600000.00 88000000.00 6145000000.00 13263500000.00 11650300000.00 6326900000.00 31240700000.00 1868900000.00 3727500000.00 234400000.00 37071500000.00 43216500000.00 137566500000.00 1. The above audited consolidated financial results of the Company were reviewed and recommended by the Audit Committee on 18 May 2023 and subsequently approved by the Board of Directors at its meeting held on 19 May 2023. The auditors have expressed an unmodified opinion on the financial results for the year ended 31 March 2023. The figures for the quarter ended 31 March 2023 and 31 March 2022 are balancing figures between audited figures in respect of full financial year and the unaudited published year-to-date figures up to 31 December 2022 and 31 December 2021 respectively, which were subjected to limited review. 2. The Company has entered into a Securities Subscription Agreement and Shareholders’ Agreement dated 23 December 2022 with Enzene Biosciences Limited, a subsidiary of the Company (“Enzene”), Eight Roads Ventures India Healthcare IV, L.P. (“Eight Roads Ventures”) and F-Prime Capital Partners Life Sciences Fund VI LP (“F-Prime Capital”) towards subscription of Compulsorily Convertible Preference Shares (‘CCPS’) by Eight Roads Ventures and F-Prime Capital in Enzene for a consideration of Rs.1,614.8 million which is equivalent to 8% of the subsidiary’s equity valuation. 3. The Group has considered indicators of impairment of its cash-generating units for factors like decline in operational performance, changes in the outlook of future profitability, and weaker market conditions, among other potential indicators. In respect of one of the manufacturing units located at St. Louis under S & B Pharma LLC, USA, a step-down subsidiary of the Company, where indicators of impairment were identified, the Group estimated the recoverable amount of the assets based on the fair value less costs to sell. The outcome of this exercise as on 31 March 2023 resulted in the Group recognizing an impairment loss of Rs 1,029.8 Million in the consolidated financial results under ‘Exceptional item’. Consequently, deferred tax assets pertaining to the above assets are no longer available for utilisation, have been derecognised in the consolidated financial statements amounting to Rs. 1,197.2 mn During the previous year, the Group has fair valued one of its investments in the USA and considering the contingencies on business projections of the investee company an amount of Rs. 149.6 million has been debited to the Statement of Profit and Loss and disclosed as an ‘Exceptional item’. 4. During the quarter ended 31 March 2023, the Company has paid a Special Dividend of Rs. 25 (Rupees Twenty five only) per equity share. In addition to the Special Dividend, the Company has also paid an interim dividend of Rs. 15 (Rupees Fifteen only) per equity share amounting to a total interim dividend of Rs. 40 (Rupees Forty only) per equity share (2000% on the face value of Rs. 2 each) for the financial year ended 31 March 2023. The Board of Directors at its meeting held on 19 May 2023 has recommended a final dividend of Rs. 10 (Rupees Ten only) per equity share (500% on the face value of Rs. 2 each) for the financial year 2022-23. 5. The Group operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. 1073568000.00 4734085000.00 -1347056000.00 0.00 0.00 -769975000.00 0.00 0.00 0.00 145080000.00 0.00 0.00 0.00 3104190000.00 0.00 505703000.00 0.00 0.00 0.00 -405805000.00 1905000.00 1711386000.00 0.00 0.00 0.00 0.00 1184674000.00 0.00 0.00 6511173000.00 19558873000.00 0.00 0.00 0.00 2733873000.00 0.00 16825000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 32048000.00 2329087000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2175278000.00 0.00 0.00 0.00 0.00 0.00 1923000.00 1469138000.00 0.00 4129657000.00 0.00 1128401000.00 0.00 0.00 1614795000.00 0.00 0.00 0.00 0.00 0.00 -12689813000.00 95021000.00 0.00 238341000.00 5295200000.00 904609000.00 0.00 0.00 -17608189000.00 345212000.00 70957000.00 416169000.00 2321831000.00 2738000000.00 Remeasurements of defined benefit plans -13800000.00 Remeasurements of defined benefit plans -48700000.00 -13800000.00 -48700000.00 -4300000.00 -16100000.00 Foreign currency translation difference of foreign operations -93500000.00 Foreign currency translation difference of foreign operations 1181600000.00 -93500000.00 1181600000.00 0.00 0.00